Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bone Marrow Disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44352   clinical trials with a EudraCT protocol, of which   7379   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    3,167 result(s) found for: Bone Marrow Disease. Displaying page 73 of 159.
    «« First « Previous 69  70  71  72  73  74  75  76  77  Next» Last»»
    EudraCT Number: 2012-000793-30 Sponsor Protocol Number: IntReALL-SR-2010 Start Date*: 2013-10-25
    Sponsor Name:Charité - University Hospital of Berlin
    Full Title: International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010
    Medical condition: Acute lymphoblastic leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10063626 Acute lymphocytic leukemia recurrent LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) PT (Completed) GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) AT (Completed) IE (Completed) FI (Completed) DK (Completed) CZ (Completed) IT (Completed) NL (Completed) FR (Completed) PL (Completed) ES (Prematurely Ended) NO (Completed)
    Trial results: View results
    EudraCT Number: 2015-001360-19 Sponsor Protocol Number: ADN011 Start Date*: 2016-01-04
    Sponsor Name:ADIENNE SA
    Full Title: Prospective, phase II/III, randomized clinical study to compare BEGEDINA® versus “conventional treatment” for treating steroid resistant acute graft-versus host disease
    Medical condition: steroid resistant acute graft versus host disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021428 - Immune system disorders 10066260 Acute graft versus host disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001896-35 Sponsor Protocol Number: ETOP3-12 Start Date*: 2012-08-29
    Sponsor Name:ETOP (European Thoracic Oncology Platform)
    Full Title: A randomized phase III trial of erlotinib versus docetaxel in patients with advanced squamous cell non-small cell lung cancer who failed first line platinum based doublet chemotherapy stratified by...
    Medical condition: Squamous cell non-small cell lung cancer in patients who have failed first-line platinum-based doublet chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) IE (Completed) AT (Completed) ES (Completed) NL (Prematurely Ended) DE (Completed) IT (Completed) DK (Prematurely Ended) GB (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002544-32 Sponsor Protocol Number: UCL/15/0515 Start Date*: 2018-03-01
    Sponsor Name:University College London
    Full Title: A phase II study of nivolumab monotherapy in patients with relapsed/refractory Hodgkin lymphoma, fit for autologous stem cell transplant, who fail to reach complete metabolic remission after first ...
    Medical condition: Relapsed/refractory Hodgkin lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020266 Hodgkin's disease recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020267 Hodgkin's disease refractory PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-001725-24 Sponsor Protocol Number: CTKI258AIC02 Start Date*: 2011-10-03
    Sponsor Name:Novartis Pharma Services
    Full Title: DOVIGIST: Phase II trial to evaluate the efficacy and safety of Dovitinib (TKI258) in patients with gastrointestinal stromal tumors refractory and/or intolerant to imatinib
    Medical condition: Unresectable, metastatic or recurrent gastrointestinal stromal tumor (GIST)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062427 Gastrointestinal stromal tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) FI (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003242-25 Sponsor Protocol Number: GITuD-20172019 Start Date*: 2018-03-02
    Sponsor Name:ASOCIACION GITuD
    Full Title: Analysis of 2nd line panitumumab + FOLFIRI efficacy in wild type RAS converted subjects from initially mutated RAS subjects with metastatic colorectal cancer treated in 1st line with standard FOLFO...
    Medical condition: Wild-type RAS metastatic colorectal cancer (mCRC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001267-63 Sponsor Protocol Number: SIOPENRNET001 Start Date*: 2005-07-15
    Sponsor Name:St. Anna Kinderspital
    Full Title: Bridging study using ch14.18/CHO antibody in children with refractory neuroblastoma
    Medical condition: neuroblastoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001639-38 Sponsor Protocol Number: GEMCAD-16-03 Start Date*: 2017-07-19
    Sponsor Name:Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD)
    Full Title: A phase II trial to evaluate the efficacy and safety of FOLFIRI + panitumumab as first-line treatment in elderly patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer and good ...
    Medical condition: First-line treatment in elderly patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer and good performance status
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2021-002895-38 Sponsor Protocol Number: C4671005 Start Date*: 2021-08-23
    Sponsor Name:Pfizer Inc.
    Full Title: AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF-07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTI...
    Medical condition: Coronavirus Disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) CZ (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2021-000986-34 Sponsor Protocol Number: CaboAveNEC Start Date*: 2021-12-16
    Sponsor Name:University Medical Center of the Johannes Gutenberg-University Mainz
    Full Title: A phase II, open-label, multicenter trial to investigate the clinical activity and safety of Cabozantinib in combination with avelumab in patients refractory to standard chemotherapy with advanced ...
    Medical condition: Advanced neuroendocrine neoplasias G3 (NEN G3) (excluding SCLC and Merkel cell carcinomas)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057270 Neuroendocrine carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003149-56 Sponsor Protocol Number: OLYMP-1 Start Date*: 2018-05-14
    Sponsor Name:University Hospital Ulm
    Full Title: OBINUTUZUMAB in MARGINAL ZONE LYMPHOMA
    Medical condition: Marginal Zone Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062113 Splenic marginal zone lymphoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076596 Marginal zone lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-001768-31 Sponsor Protocol Number: ZENO-01 Start Date*: 2012-09-03
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: ZENO-01 90Y ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of Mucosa associated lymphoid tissue (MALT Lymphoma)
    Medical condition: MALT Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060707 MALT lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001995-23 Sponsor Protocol Number: NIBIT-MESO-1 Start Date*: Information not available in EudraCT
    Sponsor Name:FONDAZIONE NIBIT NETWORK ITALIANO PER LA BIOTERAPIA DEI TUMORI
    Full Title: A SINGLE ARM, PHASE II CLINICAL STUDY OF TREMELIMUMAB COMBINED WITH THE ANTI-PD-L1 MEDI4736 MONOCLONAL ANTIBODY IN UNRESECTABLE MALIGNANT MESOTHELIOMA SUBJECTS: NIBIT-MESO-1 STUDY
    Medical condition: UNRESECTABLE MALIGNANT MESOTHELIOMA
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027406 Mesothelioma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003618-37 Sponsor Protocol Number: SARS-CoV-2_booster_IS Start Date*: 2021-06-30
    Sponsor Name:Oslo University Hospital
    Full Title: REVACCINATION OF IMMUNOSUPPRESSED PATIENTS WITH POOR/NO SARS-COV-2 VACCINE RESPONSE.
    Medical condition: Patients with immune deficiency without proper response to previous SARS-CoV-2 vaccine doses.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10003816 Autoimmune disorders HLGT
    20.0 10022117 - Injury, poisoning and procedural complications 10074555 Transplantation complication PT
    20.0 100000004851 10003921 B-cell unclassifiable lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004954-34 Sponsor Protocol Number: 28981 Start Date*: 2008-12-12
    Sponsor Name:Merck Serono S.A. - Geneva, an affiliate of Merck KGaA, Darmstadt, Germany
    Full Title: Double-blind extension of the study 27025 (REFLEX) to obtain long-term follow-up data in patients with clinically definite MS and patients with a first demyelinating event at high risk of convertin...
    Medical condition: Subjects of high risk of converting to Multiple Sclerosis or subjects already converted to Multiple Sclerosis.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) AT (Completed) FI (Completed) ES (Completed) PT (Completed) EE (Completed) DE (Completed) BE (Completed) LV (Completed) GR (Completed) IT (Completed) FR (Completed) BG (Completed) PL (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2014-001394-13 Sponsor Protocol Number: C16021 Start Date*: 2015-08-12
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell...
    Medical condition: Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) CZ (Completed) AT (Completed) PT (Completed) DK (Completed) ES (Completed) SE (Completed) HU (Completed) FR (Completed) HR (Prematurely Ended) PL (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019348-37 Sponsor Protocol Number: CLDE225X2104 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase 1 study of LDE225 in pediatric patients with recurrent or refractory medulloblastoma or other tumors potentially dependent on the Hedgehog-signaling pathway
    Medical condition: pediatric patients with recurrent or refractory medulloblastoma or other tumors potentially dependent on the Hedgehog-signaling pathway (rhabdomyosarcoma, neuroblastoma, hepatoblastoma, high-grade ...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066594 Medulloblastoma recurrent LLT
    12.1 10039027 Rhabdomyosarcoma recurrent LLT
    12.1 10066595 Neuroblastoma recurrent LLT
    12.1 10065443 Malignant glioma LLT
    12.1 10031296 Osteosarcoma recurrent LLT
    12.1 10019823 Hepatoblastoma recurrent LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001284-23 Sponsor Protocol Number: XM22-ONC-305 Start Date*: 2013-12-10
    Sponsor Name:Merckle GmbH
    Full Title: A randomized, phase IIIB, open-label, two-arm, multicenter, comparatiVe study on efficacy and safety of lipegfilgrastim (Lonquex, TEVA) in comparison to pegfilgrastim (Neulasta®, Amgen) in elderly ...
    Medical condition: The study population includes patients with aggressive B cell Non-Hodgkin Lymphoma (NHL) planned to receive systemic anti-cancer therapy with at least 6 cycles of R-CHOP-21, according to local stan...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10066481 Hematological malignancy LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003659-13 Sponsor Protocol Number: IMG-7289-CTP-201 Start Date*: 2020-06-21
    Sponsor Name:Imago BioSciences Inc.
    Full Title: A Phase 2 Multi-Center, Open Label Study to Assess the Safety,Efficacy and Pharmacodynamics of IMG-7289 in Patients with Essential Thrombocythemia
    Medical condition: Patients with essential thrombocythemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10015494 Essential thrombocythemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004139-62 Sponsor Protocol Number: CRAD001JES13 Start Date*: 2014-01-02
    Sponsor Name:Novartis Farmacéutica S. A.
    Full Title: A pilot open-label, phase II, single-arm study to evaluate the association of biomarkers of hormonal resistance and the mTOR pathway with the clinical efficacy of everolimus plus letrozole in the f...
    Medical condition: Estrogen receptor or progesterone receptor positive locally advanced or metastatic breast cancer in postmenopausal women
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 69  70  71  72  73  74  75  76  77  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Aug 02 09:55:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA